Applied Molecular Transport, LLC, has entered into a research collaboration and license agreement granting Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license for an orally administered biopharmaceutical product candidate engineered for the treatment of inflammatory bowel diseases.

Applied Molecular Transport’s technology, TRANSINT, enables the development of oral biopharmaceuticals and RNA therapeutics for local gastrointestinal targeting or systemic release. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, California, Applied Molecular Transport is eligible to receive upfront license fees, support for research activities conducted in collaboration with Janssen immunology scientists, and milestone payments upon achievement of defined development, regulatory,and commercialization milestones, plus tiered royalties on worldwide sales.

In January 2015. Applied Molecular Transport moved into new office and laboratory space in the JLabs (Janssen Labs) incubator in the biotech hub of South San Francisco, California,

Source: Applied Molecular Transport